© Reuters. FILE PHOTO: Test tubes are seen in front of a displayed Biontech logo in this illustration taken, May 21, 2021. REUTERS/Dado Ruvic/Illustration/File Photo
FRANKFURT (Reuters) – Germany’s BioNTech SE (NASDAQ:) said the COVID-19 vaccine it is developing with partner Pfizer (NYSE:) will likely generate up to 17 billion euros ($19.6 billion) in revenues this year, as booster shots take hold and use in children increases.
Based on planned deliveries of up to 2.5 billion doses so far, BioNTech said in a statement on Tuesday that it expects 16 billion to 17 billion euros in revenue accruing to it from the vaccine this year, up from a forecast in August of 15.9 billion euros.
That figure includes milestone payments from partners and a share of gross profit in its partners’ territories, the company added.
Pfizer, for its part, last week said it expected to book $36 billion in 2021 sales of the COVID-19 vaccine and forecast another $29 billion from the shot in 2022, topping analyst estimates for both years.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Be the first to comment